RCUS
NYSEArcus Biosciences Inc.
Price$25.14-0.60 (-2.33%)
01:30 PM07:45 PM
News · 26 weeks79+75%
2025-10-262026-04-19
Mix2890d
- SEC Filings10(36%)
- Other7(25%)
- Insider7(25%)
- Earnings3(11%)
- Analyst1(4%)
Latest news
25 items- SECSEC Form 144 filed by Arcus Biosciences Inc.144 - Arcus Biosciences, Inc. (0001724521) (Subject)
- SECSEC Form DEFA14A filed by Arcus Biosciences Inc.DEFA14A - Arcus Biosciences, Inc. (0001724521) (Filer)
- SECSEC Form DEF 14A filed by Arcus Biosciences Inc.DEF 14A - Arcus Biosciences, Inc. (0001724521) (Filer)
- PRArcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline UpdatesArcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will host a conference call and webcast on Tuesday, May 5, 2026 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline updates for the quarter ended March 31st, 2026. Investors interested in listening to the conference call may do so by dialing +1 (585) 542-9983 (local) or +1 (833) 461-5787 (toll-free), using Meeting ID: 304747896. Participants may also register for the call online using the follow
- SECArcus Biosciences Inc. filed SEC Form 8-K: Other Events8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
- PRArcus Biosciences Announces New Employment Inducement GrantsArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 7,850 shares of the Company's common stock at an exercise price per share of $22.65, which was the closing price on April 8, 2026, and restricted stock units to acquire a total of 3,950 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Comp
- SECSEC Form 144 filed by Arcus Biosciences Inc.144 - Arcus Biosciences, Inc. (0001724521) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Arcus Biosciences Inc.SCHEDULE 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)
- PRArcus Biosciences Announces New Employment Inducement GrantsArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune disorders, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 7,050 shares of the Company's common stock at an exercise price per share of $21.41, which was the closing price on March 23, 2026, and restricted stock units to acquire a total of 3,550 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the C
- SECArcus Biosciences Inc. filed SEC Form 8-K: Leadership Update8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
- PRArcus Biosciences Announces New Employment Inducement GrantsArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 17,050 shares of the Company's common stock at an exercise price per share of $23.43, which was the closing price on March 9, 2026, and restricted stock units to acquire a total of 8,550 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Co
- PRArcus Biosciences to Participate in Two Upcoming Investor ConferencesArcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in March: Leerink Global Healthcare Conference 2026 Date: Monday, March 9th, 2026 Location: Miami, FL Format: Fireside chat & 1x1 meetings Time: 11:20 a.m. ET Barclays 28th Annual Global Healthcare Conference Date: Tuesday, March 10th, 2026 Location: Miami Beach, FL Format: 1x1 meetings A live webcast of the fireside chat will be available by visiting the "Investors & M
- SECSEC Form S-3ASR filed by Arcus Biosciences Inc.S-3ASR - Arcus Biosciences, Inc. (0001724521) (Filer)
- SECSEC Form S-8 filed by Arcus Biosciences Inc.S-8 - Arcus Biosciences, Inc. (0001724521) (Filer)
- SECSEC Form 10-K filed by Arcus Biosciences Inc.10-K - Arcus Biosciences, Inc. (0001724521) (Filer)
- SECArcus Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
- PRArcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline UpdateUpdated data for casdatifan in late-line kidney cancer demonstrated median progression-free survival (PFS) of 15.1 months and a confirmed overall response rate (cORR) of 45% for the 100mg once-daily (QD) cohort At least two additional data presentations for casdatifan are expected in 2026: updated data for casdatifan plus cabozantinib and initial data in early-line kidney cancer In addition to the ongoing Phase 3 PEAK-1 study, Arcus plans to initiate a Phase 3 study in the first-line (1L) metastatic setting evaluating casdatifan in a tyrosine kinase inhibitor (TKI)-free combination by the end of 2026 With $1.0 billion in cash, cash equivalents and marketable securities at year-
- PRArcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney CancerMedian progression-free survival (mPFS) was 15.1 months, and the confirmed overall response rate (cORR) increased to 45% for the 100mg QD (once daily) tablet cohort in an updated analysis of the ARC-20 study In a pooled analysis of all four monotherapy cohorts (n=121), casdatifan data were better on every efficacy measure evaluated relative to published data from studies with the only marketed HIF-2a inhibitor New biomarker data demonstrated correlation between magnitude and durability of serum erythropoietin (sEPO) suppression by casdatifan and clinical benefit, including cORR and PFS Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focuse
- ANALYSTArcus Biosciences downgraded by Wells Fargo with a new price targetWells Fargo downgraded Arcus Biosciences from Overweight to Equal Weight and set a new price target of $23.00
- PRArcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline UpdatesArcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will host a conference call and webcast on Wednesday, February 25th, 2026 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline update for the quarter and year ended December 31st, 2025. Investors interested in listening to the conference call may do so by dialing +1 (646) 844-6383 (local) or +1 (833) 470-1428 (toll-free), using Access Code: 190500. Participants may also register for the call onli
- INSIDERChief Executive Officer Rosen Terry J was granted 79,000 shares, increasing direct ownership by 4% to 2,236,409 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- INSIDERChief Medical Officer Markus Richard was granted 24,000 shares, increasing direct ownership by 37% to 89,647 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- INSIDERGeneral Counsel Tang Carolyn C. was granted 24,000 shares, increasing direct ownership by 19% to 148,734 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- INSIDERChief Financial Officer Goeltz Ii Robert C. was granted 24,000 shares, increasing direct ownership by 35% to 91,924 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- INSIDERChief Operating Officer Jarrett Jennifer was granted 31,000 shares, increasing direct ownership by 16% to 224,024 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)